Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug
Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
News February 11
Latest In: cannabinoid
Massachusetts issues cease-and-desist order to hemp manufacturer using THCV
Massachusetts regulators have issued a cease-and-desist order to a licensed hemp manufacturer in the state to halt the…
News May 13
Kentucky governor signs law establishing delta-8 guidelines
Kentucky's governor signed a bill into law that establishes a framework to test, label and regulate delta-8 and…
News March 24
Johnson & Johnson asks FDA to ‘chip away’ at cannabinoid regulations
Drugmaker Johnson & Johnson has joined the chorus of businesses asking U.S. health regulators to develop basic safety…
News June 15
FDA takes another look at CBD, but insiders are skeptical much will change
U.S. health regulators are taking their closest look in more than three years at the idea of incorporating…
News June 14
Lygos CBx scales up bio-based production of cannabinoids
A San Francisco Bay Area company that specializes in low-cost alternatives to plant-derived cannabinoids has launched commercial-scale production.…
News April 5Featured
Latest Sponsored
